22 Jul, 2026
According to Straits Research, the global liver cirrhosis treatment market was valued at USD 19.90 billion in 2025 and is projected to grow from USD 21.15 billion in 2026 to USD 34.81 billion by 2034, registering a CAGR of 6.43% during the forecast period (2026–2034).
The market is expanding steadily due to the increasing prevalence of chronic liver diseases, rising alcohol consumption, growing cases of viral hepatitis, and continuous advancements in pharmaceutical treatments.
Liver cirrhosis treatment involves medical therapies and supportive care used to manage liver damage, reduce complications, and improve the quality of life of patients with cirrhosis. Since cirrhosis causes permanent scarring of the liver, treatment mainly focuses on slowing disease progression, controlling symptoms, treating the underlying cause, and preventing liver failure.
Common treatment options include immunosuppressants, antibiotics, corticosteroids, vaccines, and other supportive medications. In severe cases, patients may require liver transplantation. Early diagnosis and timely treatment play an important role in improving long-term patient outcomes.
The global liver cirrhosis treatment market is witnessing stable growth as liver diseases continue to affect millions of people worldwide. The increasing incidence of alcoholic liver disease, hepatitis B and C infections, obesity, and non-alcoholic fatty liver disease (NAFLD) has significantly increased the number of patients requiring long-term treatment.
One of the major drivers of market growth is the growing demand for advanced drug therapies that reduce liver inflammation and slow disease progression. Pharmaceutical companies are investing heavily in research and development to introduce more effective therapies targeting fibrosis, inflammation, and immune-related liver damage.
The rising awareness of liver health and increasing availability of diagnostic technologies are also contributing to market expansion. Improved screening programs enable earlier diagnosis, allowing patients to begin treatment before severe complications develop.
North America currently dominates the liver cirrhosis treatment market, accounting for the largest market share in 2025 due to its advanced healthcare infrastructure, high healthcare spending, strong pharmaceutical industry, and growing number of liver disease patients.
Asia-Pacific is expected to witness the fastest growth during the forecast period because of increasing healthcare investments, expanding patient populations, and improving access to advanced medical treatments.
The contents of the report are as follows:
By Treatment Type
By Disease Type
By Distribution Channel
By Region
sales@straitsresearch.com